published this morning is mostly responsible for today's action, in my opinion. It's a great review of Novavax and its huge potential. Sugggest you all read it. Especially you sorry shorties who should be covering in droves.
Rez, what you say about the article is valid, IMHO. The article was very well written and very positive. The article was well written in being a great non-technical summary of why Novavax is a good buy.
IMHO, the most positive sentence in the article is "Novavax's platform has been broadly validated and its regulatory pathway has been vetted by a major player in the pharma world."
Retail buyers use this type of article to decide about buying or not buying into a company. This morning's action during "amateur hour" illustrates, IMHO, more retail awareness of Novavax. The pullback since that initial buying is normal and no concern to me. We'll see much more buying as time goes along.
Now, the fight for more shares is between institutions and retail. Fur is going to fly....
IMO what is really huge about it is that the Fool wrote a truly positive piece about NVAX. Previously, everything written by them was more like a back-handed compliment. Are the stars finally aligning?